Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 Inhibition

BackgroundCyclin-dependent kinase 7 (CDK7) is crucial for cell cycle progression and gene expression transcriptional regulation, which are often not assessed in cancer developing process. CDK7 inhibitors have emerged as promising drugs for treating diverse cancers, including breast cancer. However,...

詳細記述

書誌詳細

出版年:	Frontiers in Oncology
主要な著者:	Jingyu Peng, Ming Yang, Ran Bi, Yueyuan Wang, Chunxi Wang, Xue Wei, Zhihao Zhang, Xiao Xie, Wei Wei
フォーマット:	論文
言語:	英語
出版事項:	Frontiers Media S.A. 2021-05-01
主題:	CDK7 inhibition THZ1 triple-negative breast cancer mutated p53 targeted therapy cancer treatment
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fonc.2021.664848/full